Ulhaq
Farman Ulhaq, New York, NY US
Patent application number | Description | Published |
---|---|---|
20100198716 | System and Method of Coordinating the Trading of Securities and Instruments with Disparate Communication Modalities - A method and system of networking various users trading securities such as short-term adjustable rate securities, longer term fixed income securities, and other instruments. A plurality of instances of trading software residing on one or more computers accessible by a plurality of users are connected to a centralized hub having at least one database. On the database are stored a plurality of user profiles, each of the profiles including at least messaging preferences of the respective users. Trading messages may be sent in a first format from a first sending user to the centralized hub. At the hub, at least one second recipient user of the trading message is determined. The sent message is then transmitted from the hub to the at least one second recipient user in accordance with the at least one second recipient user's user profile stored on the hub. | 08-05-2010 |
Saraj Ulhaq, Monifieth GB
Patent application number | Description | Published |
---|---|---|
20100305070 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS - The disclosure relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. Also provided are pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. Provided are methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1B1 and allelic variants thereof. Finally, provided is a method for determining the efficacy of a compound as described herein in treating cancer. | 12-02-2010 |
Saraj Ulhaq, Dundee GB
Patent application number | Description | Published |
---|---|---|
20120190639 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS - The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer. | 07-26-2012 |
20120302748 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS - The disclosure relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. Also provided are pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. Provided are methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1B1 and allelic variants thereof. Finally, provided is a method for determining the efficacy of a compound as described herein in treating cancer. | 11-29-2012 |